The impact of COVID-19 monoclonal antibodies on clinical outcomes: A retrospective cohort study

Abstract: The impact of COVID-19 monoclonal antibodies on clinical outcomes: A retrospective cohort study Arielle R. Nagler, MD, The Ronald O. Perelman Department of Dermatology, NYU Grossman t us cr ip Leora I. Horwitz, MD, MHS, Department of Medicine and Department of Population Health, NYU Grossman School of Medicine, New York, NY, USA Simon Jones, PhD, Department of Population Health, NYU Grossman School of Medicine, M an New York, NY, USA d Christopher M. Petrilli, MD, NYU Grossman School of Medicine, New York, NY, USA ce York, NY, USA pt e Eduardo Iturrate, MD, Department of Medicine, NYU Grossman School of Medicine, New Ac Jennifer L. Lighter, MD, Division of Pediatric Infectious Diseases, Department of Pediatrics, NYU Grossman School of Medicine, New York, NY, USA Michael Phillips, MD, Division of Infectious Disease, Department of Medicine, NYU Grossman School of Medicine, New York, NY, USA © American Society of Health-System Pharmacists 2022. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. School of Medicine, New York, NY, USA Brian P. Bosworth, MD, Department of Medicine, NYU Grossman School of Medicine, New York, NY, and NYU Langone Health, New York, NY, USA Bruce Polsky, MD, Department of Medicine, NYU Long Island School of Medicine, New York, t us cr ip Frank M. Volpicelli, MD, Department of Medicine, NYU Grossman School of Medicine, New York, NY, USA an Isaac Dapkins, MD, Family Health Centers at NYU Langone, Brooklyn, NY, USA M Anand Viswanathan, MD, Department of Medicine, NYU Grossman School of Medicine, pt e d New York, NY, USA Fritz François, MD, Department of Medicine, NYU Grossman School of Medicine, New York, ce NY, and NYU Langone Health, New York, NY, USA Ac Gary Kalkut, MD, MPH, Division of Infectious Disease, Department of Medicine, NYU Grossman School of Medicine, New York, NY, and NYU Langone Health, New York, NY, USA Address correspondence to Dr. Nagler (Arielle.Nagler@nyumc.org). Twitter: @ArielleNaglerMD NY, USA Purpose: Despite progress in the treatment of coronavirus disease 2019 (COVID-19), including the development of monoclonal antibodies (mAbs), more clinical data to support the use of mAbs in outpatients with COVID-19 is needed. This study is designed to determine the impact of bamlanivimab, bamlanivimab/etesevimab, or t Methods: A retrospective cohort study was conducted at a single academic medical center us cr ip with 3 campuses in Manhattan, Brooklyn, and Long Island, NY. Patients 12 years of age or older who tested positive for COVID-19 or were treated with a COVID-19–specific therapy, including COVID-19 mAb therapies, at the study site between November 24, 2020, and May 15, 2021, were included. The primary outcomes included rates of emergency department M from the date of COVID-19 diagnosis. an (ED) visit, inpatient admission, intensive care unit (ICU) admission, or death within 30 days Results: A total of 1,344 mAb-treated patients were propensity matched to 1,344 patients d with COVID-19 patients who were not treated with mAb therapy. Within 30 days of pt e diagnosis, among the patients who received mAb therapy, 101 (7.5%) presented to the ED and 79 (5.9%) were admitted...